TOP TEN perturbations for 38629_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38629_at
Selected probe(set): 203929_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38629_at (203929_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
stem cell differentiation study 59 (iDRG; 15d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):5.5724697Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 15d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper. | |
| Control | normal embryonic stem cell sample (WA09) |
| Undifferentiated WA09 embryonic stem cell samples. |
stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):5.2438946Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 12d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
| Control | normal embryonic stem cell sample (WA09) |
| Undifferentiated WA09 embryonic stem cell samples. |
stem cell differentiation study 59 (iDRG; 15d) / stem cell differentiation study 59 (8d)
Relative Expression (log2-ratio):4.1664743Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 15d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper. | |
| Control | stem cell differentiation study 59 (8d) |
| WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper. |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.9401054Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
stem cell differentiation study 59 (iDRG; 12d) / stem cell differentiation study 59 (8d)
Relative Expression (log2-ratio):3.8378992Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 12d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
| Control | stem cell differentiation study 59 (8d) |
| WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper. |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.752283Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.587Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
basal cell carcinoma study 3 / normal epidermal keratinocytes
Relative Expression (log2-ratio):3.4932451Number of Samples:4 / 2
| Experimental | basal cell carcinoma study 3 |
| Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC). | |
| Control | normal epidermal keratinocytes |
| Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2. |
breast cancer study 50 (subtype V) / breast cancer study 50 (subtype I)
Relative Expression (log2-ratio):3.4263277Number of Samples:41 / 37
| Experimental | breast cancer study 50 (subtype V) |
| Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype V. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype V:predominantly positive for ER, predominantly positive for PR, predominantly negative for HER2, long-term survival with hormonal therapy alone following surgery and/or radiation therapy, adjuvant chemotherapy did not provide any survival benefit in early stages, consistent with a unique subset of luminal A intrinsic type, smaller tumors dominate (T-stage), least likely to metastasize, increased expressions of cell cycle/proliferation genes, low risk of distant recurrence | |
| Control | breast cancer study 50 (subtype I) |
| Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype I. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype I:predominantly negative for ER, variable for PR expression, predominantly negative for HER2, in concordance with chemosensitive basal-like intrinsic type, CMF yielded survival outcome similar to those of CAF, increased expressions of cell cycle/proliferation genes, high risk of distant recurrence |
stem cell differentiation study 59 (iDRG; 15d) / stem cell differentiation study 59 (iDRG; 9d)
Relative Expression (log2-ratio):3.3312988Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 15d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper. | |
| Control | stem cell differentiation study 59 (iDRG; 9d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper. |